References
1. Del Pinto, R.; Pietropaoli, D.; Chandar, A.K.; et al. Association between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. Inflamm. Bowel Dis. 2015, 21, 2708–2717.
2. Reich, K.M.; Fedorak, R.N.; Madsen, K.; et al. Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J. Gastroenterol., 2014, 20, 4934-4947. DOI: 10.3748/wjg.v20.i17.4934
3. Wang, T.T.; Dabbas, B.; Laperriere, D.; et al. Direct and indirect induction by 1,25-dihydroxivitamin D3 of the NOD2/CARD15-defensin β2 innate immune pathway defective in Crohn disease. J Biol Chem., 2010, 285, 2227-2231. DOI: 10.1074/jbc.C109.071225
4. Raftery, T.; Martineau, A.R.; Greiller, C.L.; et al. Effects of vitamin D Current Drug Metabolism, 2019, Vol. 20, No. 00 Martín et al. supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised doubleblind placebo-controlled study. United European Gastroenterol. J., 2015, 3(3), 294-302.
5. Sadeghian, M.; Saneei, P.; Siassi, F.; et al. Vitamin D status in relation to Crohn´s disease: meta-analysis of observational studies. Nutrition, 2016, 32, 505-514. DOI: 10.1016/j.nut.2015.11.008
6. Gubatan J, Chou ND, Nielsen OH, et al. Systematic review with meta‐analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Oct 24. doi: 10.1111/apt.15506. [Aceptado, en prensa].
7. Hassan V, Hassan S, Seyed‐Javad P, et al. Association between serum 25 (OH) vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. Med J Malaysia. 2013;68:34‐38. PMID: 23466764
8. Jørgensen SP, Hvas CL, Agnholt J, Christensen LA, et al. Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407‐e413.
9. Hlavaty T, Krajcovicova A, Koller T, et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J Gastroenterol. doi: 10.3748/wjg.v20.i42.15787
10. Zator ZA, Cantu SM, Konijeti GG, et al. Pretreatment 25‐ Hydroxyvitamin D levels and durability of anti‐tumor necrosis factor– α therapy in inflammatory bowel diseases. J Parenter Enteral Nutr. 2014;38:385‐391. 2014;20:15787. DOI: 10.1177/0148607113504002
11. Raftery T, Merrick M, Healy M, et al. Vitamin D status is associated with intestinal inflammation as measured by fecal calprotectin in Crohn’s disease in clinical remission. Dig Dis Sci. 2015;60:2427‐2435.
12. Raffner Basson A, Swart R, Jordaan E, Mazinu M, et al. Vitamin D deficiency increases the risk for moderate to severe disease activity in Crohn's disease patients in South Africa, Measured by the Harvey Bradshaw Index. J Am Coll Nutr. 2016;35:163‐174.
13. Frigstad SO, Høivik M, Jahnsen J, et al. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. Scand J Gastroenterol. 2017;52:100‐106.
14. Meckel K, Li YC, Lim J, et al. Serum 25‐hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016;104:113‐120.
15. Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5‐year longitudinal study. Am J Gastroenterol. 2016;111:712‐719.
16. Ghaly S, Murray K, Baird A, et al. High vitamin D‐binding protein concentration, low albumin, and mode of remission predict relapse in Crohn's disease. Inflamm Bowel Dis. 2016;22:2456‐2464.
17. Ye L, Lin Z, Liu J, Cao Q. Vitamin D deficiency is associated with endoscopic severity in patients with Crohn’s disease. Gastroenterol Res Pract. 2017;1‐5.
18. Winter RW, Collins E, Cao B, et al. Higher 25‐hydroxyvitamin D levels are associated with greater odds of remission with anti‐tumour necrosis factor‐α medications among patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45:653‐659.
19. Schäffler H, Schmidt M, Huth A, et al. Clinical factors are associated with vitamin D levels in IBD patients‐ a retrospective analysis. J Dig Dis. 2017;19:24‐32.
20. Gubatan J, Mitsuhashi S, Zenlea T, et al. Low serum vitamin D During remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;15:240‐246.
21. Alrefai D, Jones J, El‐Matary W, et al. The association of vitamin D status with disease activity in a cohort of Crohn’s disease patients in Canada. Nutrients. 2017;9:1112.
22. Olmedo Martín RV, González Molero I, Olveira Fuster G, et al. Deficiencia de vitamina D en pacientes ambulatorios con enfermedad inflamatoria intestinal: prevalencia y asociación con la actividad clínica-biológica. Rev Esp Enferm Dig 2019;111(1):46-54. DOI: 10.17235/reed.2018.5714/2018
23. Bours P, Wielders J, Vermeijden JR, et al. Seasonal variation of serum 25‐hydroxyvitamin D levels in adult patients with inflammatory bowel disease. Osteoporos Int. 2011;22:2857‐2867.
24. Scolaro BL, Barretta C, Matos CH, et al. Deficiency of vitamin D and its relation with clinical and laboratory activity of inflammatory bowel diseases. Journal of Coloproctol. 2018;38:99‐104.
25. Hausmann, J.; Kubesch, A.; Amiri, M.; et al. Vitamin D Deficiency is Associated with Increased Disease Activity in Patients with Inflammatory Bowel Disease. J. Clin. Med. 2019, 8, 1319. doi: 10.3390/jcm8091319.
26. López-Muñoz, P.; Beltrán, B.; Sáez-González, et al. Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients. Nutrients 2019, 11, 1059.
27. Meckel, K.; Li, Y.C.; Kocherginsky, M.; et al. Serum 25-hydroxivitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am. J. Clin. Nutr., 2016, 104(1), 113-120.
28. Santos-Antunes, J.; Nunes, A.C.; Lopes, S. et al. The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study. Inflamm. Bowel Dis., 2016, 2(5), 1101-1106.
29. Winter, R.W.; Collins, E.; Cao, B. et a. Higher 25-hydroxivitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases. Aliment. Pharmacol. Ther., 2017, 45(5), 653-659.
30. Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease – a randomized double-blind placebocontrolled study. Aliment Pharmacol Therap 2010;32:377–83.
31. Yang, L.; Weaver, V.; Smith, J.P.; et al. Therapeutic effect of vitamin D supplementation in a pilot study of Crohn’s patients. Clin. Transl. Gastroenterol., 2013, 4:e33.
32. Dadaei, T.; Safapoor, M.H.; Asadzadeh Aghdaei, et al. Effect of vitamin D3 supplementation on TNF-α serum level and disease activity index in Iranian IBD patients. Gastroenterol. Hepatol. Bed Bench, 2015, 8(1), 49-55. PMID: 25584176
33. Sharifi A, Hosseinzadeh-Attar MJ, Vahedi H, et al. A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients. Saudi J Gastroenterol 2016;22:316–23.
34. Garg, M.: Hendy, P.; Ding, J.N.; et al. The effect of vitamin D on intestinal inflammation in patients with ulcerative colitis. J. Crohns Colitis, 2018, 12(8), 963-972.
35. Mathur, J.; Naing, S.; Mils, P.; Limsui, D. A randomized clinical trial of vitamin D3 (cholecalciferol) in ulcerative colitis patients with hypovitaminosis D3. Peer J., 2017, 5, e3654.
36. Narula, N.; Cooray, M.; Anglin, R. Impact of high-dose vitamin D3 supplementation in patients with Crohn’s disease in remission: a pilot randomized double-blind controlled study. Dig. Dis. Sci., 2017, 62, 448-455. DOI: 10.1007/s10620-016-4396-7
37. Tan, B.; Li, P.; Lv, H.; et al. Treatment of vitamin D deficiency in Chinese inflammatory bowel disease patients: a prospective, randomized, open-label pilot study. J. Dig. Dis., 2018, 19(4), 215-224.
38. Jun, J.C.; Yoon, H.; Choi, Y.J.; et al. The effect of vitamin D administration on inflammatory markers in patients with inflammatory bowel disease. Intest Res. 2019 Apr;17(2):210-217. doi: 10.5217/ir.2018.00081.
39. Li J, Chen N, Wang D et al. Efficacy of vitamin D in treatment of inflammatory bowel disease. Medicine. 2018;97:e12662.
40. Mechie NC, Mavropoulou E, Ellenrieder V et al. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment. Digestion. 2019 Sep 19:1-10. doi: 10.1159/000502515. [Epub ahead of print]
41. Limketkai BN, Singla MB, Rodriguez B et al. Levels of Vitamin D are Low After Crohn's Disease is Established But Not Before. Clin Gastroenterol Hepatol. 2019 Oct 4. pii: S1542-3565(19)31083-3. doi: 10.1016/j.cgh.2019.09.034. [Epub ahead of print]